Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Navigating the PMA Diagnostic Journey: Tests and Results

At a Glance

PMA is diagnosed through a neurological exam, EMG and nerve conduction studies, MRI scans, and sometimes genetic testing. The goal is to identify lower motor neuron changes, rule out treatable conditions that look similar, and monitor for new signs over time.

The diagnostic process for Progressive Muscular Atrophy (PMA) is often described as a “diagnosis of exclusion.” Because there is no single blood test that says “you have PMA,” doctors use a combination of electrical testing, imaging, and genetic screening to confirm the disease and—most importantly—rule out treatable conditions [1].

The Role of EMG: Your Electrical “Map”

The most important tool for evaluating your lower motor neurons is Electromyography (EMG) combined with Nerve Conduction Studies (NCS). Think of this as an electrical map of your body’s wiring.

  • Nerve Conduction Study (NCS): This test checks how well and how fast your peripheral nerves send signals. In PMA, your sensory nerves (the ones that feel touch and pain) should typically function normally [2]. If they don’t, it might point toward a different type of neuropathy [3].
  • Needle EMG: Your doctor will insert a tiny needle into various muscles to record their electrical activity. They are looking for two specific signs of lower motor neuron dysfunction:
    • Active Denervation: This indicates that muscle fibers have lost their nerve supply. It appears on the monitor as fibrillations or positive sharp waves—spontaneous electrical activity from unstable muscle fibers [4][5].
    • Chronic Reinnervation: This shows that your body is attempting to compensate. Nearby healthy nerves can grow new branches to take over for the damaged ones, creating larger-than-normal electrical signals called neurogenic motor units [6].

Importantly, an EMG only evaluates lower motor neurons and peripheral nerves. It cannot detect upper motor neuron damage in the brain. Upper motor neuron involvement is assessed primarily through your doctor’s physical neurological examination [7].

MRI: Looking for Structural Mimics

Magnetic Resonance Imaging (MRI) of the brain and spine is not used to “see” PMA directly. Instead, it is used to ensure nothing else is causing your symptoms [1].

  • Cervical Spine MRI: This is used to rule out cervical myelopathy (pressure on the spinal cord in the neck) or a tumor, which can cause muscle wasting in the hands that looks identical to a motor neuron disease [8][9].
  • Brain MRI: This helps rule out strokes, tumors, or other inflammatory brain diseases. While some specialized research MRIs can show signs of motor system changes, they are not routine diagnostic tests for PMA [1][9].

Genetic Testing: Understanding the Link

While the vast majority of PMA cases are “sporadic” (occurring by chance without a known family history), a small percentage of cases have a genetic cause [10]. These cases often overlap with the genes implicated in ALS:

  • SOD1 and C9orf72: These are among the genes linked to ALS and sometimes found in PMA [11][10].
  • SMN1: Testing for this gene helps rule out Spinal Muscular Atrophy (SMA), an inherited condition that mimics the lower motor neuron signs of PMA [12][13].

Your doctor may refer you to a genetic counselor to discuss the emotional, familial, and insurance implications of testing, and to help you decide which tests are appropriate. It is also important to know that a negative genetic panel does not entirely rule out an inherited component [14][11].

The Road Ahead: Monitoring and Follow-Up

Because a purely lower motor neuron syndrome can evolve over time, close monitoring is essential. Many specialized ALS and Neuromuscular clinics offer appointments every three months, though this cadence should be individualized based on your symptoms [15]. During these visits, your team will:

  1. Monitor Strength and Function: Tracking your daily activities and mobility [16].
  2. Respiratory Testing: Checking your breathing muscles to ensure you receive timely support [16].
  3. Repeat Exams: Performing neurological exams to look for any emerging upper motor neuron signs (like spasticity or brisk reflexes) [1][7].
  4. Cognitive Screening: Because there is an overlap between motor neuron diseases and cognitive/behavioral changes, screening tools like the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) may be offered to identify if you need extra support in managing daily routines [17][15].

If you experience sudden changes in your breathing, swallowing, or strength between scheduled visits, do not wait for your next appointment—contact your care team promptly [18].

Common questions in this guide

How is progressive muscular atrophy diagnosed if there is no single test?
There is no single blood test that confirms PMA. Clinicians combine a neurological examination with EMG and nerve conduction studies, imaging, and sometimes genetic tests to identify lower motor neuron changes and rule out other treatable conditions.
What can EMG and nerve conduction studies show in PMA?
In PMA, sensory nerves that carry feeling are usually normal on nerve conduction studies. Needle EMG may show active denervation, meaning unstable electrical activity after a muscle loses nerve supply, and chronic reinnervation, when nearby nerves branch to support affected muscle; EMG does not assess upper motor neuron changes in the brain.
Why might I need a brain or cervical spine MRI for suspected PMA?
MRI does not usually show PMA directly. Brain and cervical spine scans help rule out problems such as spinal cord pressure, tumors, stroke, or inflammation that can cause similar weakness or muscle wasting.
When is genetic testing considered for PMA?
Genetic testing may be considered when symptoms or family history suggest an inherited motor neuron condition. Tests may include SOD1 or C9orf72, which can be associated with ALS and sometimes PMA, and SMN1 to look for spinal muscular atrophy; a genetic counselor can discuss the benefits, limits, family implications, and insurance concerns. A negative panel does not completely exclude an inherited cause.
What does follow-up monitoring involve after a PMA evaluation?
Follow-up is often arranged about every three months at a neuromuscular or ALS clinic, but the schedule should match your symptoms. Visits may track strength and daily function, breathing muscle performance, new upper motor neuron signs, and cognitive or behavioral changes.
Which changes should prompt me to contact my care team before my next visit?
Contact your care team promptly if you develop a sudden change in breathing, swallowing, or strength instead of waiting for the next appointment. These changes may require earlier assessment and support.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Progressive muscular atrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many body regions currently show lower motor neuron signs on my EMG?
  2. 2.Do my EMG results show signs of 'active denervation' or 'chronic reinnervation' in muscles that I haven't noticed weakness in yet?
  3. 3.Was my MRI specifically looking for structural mimics like cervical myelopathy or nerve compression?
  4. 4.Given my family history and current symptoms, would meeting with a genetic counselor be appropriate to discuss testing for genes like C9orf72, SOD1, or SMN1?
  5. 5.During my physical exams, are you seeing any upper motor neuron signs that might change my diagnosis?

References

References (18)
  1. 1

    [Motor neuron diseases from a radiological perspective : Focus on amyotrophic lateral sclerosis].

    Warmann S

    Radiologie (Heidelberg, Germany) 2026; (66(4)):272-277 doi:10.1007/s00117-026-01577-8.

    PMID: 41714394
  2. 2

    Motor neuropathies and lower motor neuron syndromes.

    Verschueren A

    Revue neurologique 2017; (173(5)):320-325 doi:10.1016/j.neurol.2017.03.018.

    PMID: 28434507
  3. 3

    Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy.

    Seki S, Kitaoka Y, Kawata S, et al.

    Biomedicines 2023; (11(11)) doi:10.3390/biomedicines11112967.

    PMID: 38001967
  4. 4

    Awaji criteria for the diagnosis of amyotrophic lateral sclerosis in Hanoi, Vietnam.

    Van Nguyen T, Tran TA, Vu HT

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(1)):393-398 doi:10.1007/s10072-021-05333-9.

    PMID: 34023955
  5. 5

    Amyotrophic lateral sclerosis or not: Keys for the diagnosis.

    Lenglet T, Camdessanché JP

    Revue neurologique 2017; (173(5)):280-287 doi:10.1016/j.neurol.2017.04.003.

    PMID: 28461025
  6. 6

    [Electrodiagnostic support in an atypical form of amyotrophic lateral sclerosis (Vulpian-Bernhardt syndrome)].

    Aguilar-Vázquez CA, Aguilar-Castillo SJ, Raymundo-Carrillo AD

    Revista medica del Instituto Mexicano del Seguro Social 2024; (62(1)):1-8.

    PMID: 39116263
  7. 7

    Progressive Muscular Atrophy.

    Liewluck T, Saperstein DS

    Neurologic clinics 2015; (33(4)):761-73.

    PMID: 26515620
  8. 8

    Amyotrophic lateral sclerosis and degenerative cervical myelopathy: phenotype-based diagnostic pitfalls, investigative mismatch, and practical clinical reasoning.

    Chen D, Shen T, Ren H, Qiu P

    Frontiers in neurology 2026; (17()):1901811 doi:10.3389/fneur.2026.1901811.

    PMID: 42625715
  9. 9

    Motor Neuron Diseases and Central Nervous System Tractopathies: Clinical-Radiologic Correlation and Diagnostic Approach.

    Desai AB, Agarwal A, Mohamed AS, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240067 doi:10.1148/rg.240067.

    PMID: 39636751
  10. 10

    An SPG7 mutation as a novel cause of monogenic progressive muscular atrophy.

    Pereira Â, Tkachenko N, Fortuna AM, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(9)):3303-3305 doi:10.1007/s10072-023-06867-w.

    PMID: 37213040
  11. 11

    Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis.

    Volk AE, Weishaupt JH, Andersen PM, et al.

    Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V 2018; (30(2)):252-258 doi:10.1007/s11825-018-0185-3.

    PMID: 30220791
  12. 12

    Anterior Horn Cell Disease in Adulthood: Unmasking Spinal Muscular Atrophy Type 4.

    Rafique S, Odeh A

    Cureus 2026; (18(3)):e105356 doi:10.7759/cureus.105356.

    PMID: 42005122
  13. 13

    SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis.

    Bos JW, Groen EJN, Wadman RI, et al.

    Neurology. Genetics 2021; (7(4)):e598 doi:10.1212/NXG.0000000000000598.

    PMID: 34169148
  14. 14

    Pre-symptomatic diagnosis in ALS.

    Corcia P, Lumbroso S, Cazeneuve C, et al.

    Revue neurologique 2020; (176(3)):166-169 doi:10.1016/j.neurol.2019.07.027.

    PMID: 31932031
  15. 15

    Temporal course of cognitive and behavioural changes in motor neuron diseases.

    McHutchison CA, Wuu J, McMillan CT, et al.

    Journal of neurology, neurosurgery, and psychiatry 2024; (95(4)):316-324 doi:10.1136/jnnp-2023-331697.

    PMID: 37827570
  16. 16

    Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.

    Talman P, Duong T, Vucic S, et al.

    BMJ open 2016; (6(9)):e012054 doi:10.1136/bmjopen-2016-012054.

    PMID: 27694488
  17. 17

    Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes.

    de Vries BS, Rustemeijer LMM, Bakker LA, et al.

    Journal of neurology, neurosurgery, and psychiatry 2019; (90(2)):141-147 doi:10.1136/jnnp-2018-318788.

    PMID: 30076267
  18. 18

    Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria.

    Cortés-Vicente E, Pradas J, Marín-Lahoz J, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(5-6)):333-340 doi:10.1080/21678421.2017.1316408.

    PMID: 28440098

This page is for informational purposes only and does not constitute medical advice. Your neurologist and care team should interpret your EMG, MRI, and genetic results and decide which tests or follow-up are appropriate.